Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Four Patent Applications Related to RNAi: Aug 21, 2008

Title: Cloning and Characterization of microRNAs from Rice
Number: 7,414,125
Filed: March 29, 2006
Lead Inventor: Jian-Kang Zhu, University of California, Riverside
The invention “provides new miRNAs in rice,” according to the patent’s abstract. Additionally, “the nucleic acids of the invention can be used to control gene expression in plants.”

Title: Highly Potent hsiRNA Mixtures and Method for Gene Splicing
Number: 20080194028
Filed: Feb. 14, 2005 PCT Filed: Feb. 14, 2005
Lead Inventor: George Tzertzinis, New England Biolabs
The patent application, its abstract states, claims a method of making and use a composition having “a plurality of dsRNA fragments with overlapping sequences, each fragment having a size in the range of 18-30 [nucleotides], such that the composition is formed by enzymatic digestion of one or more large dsRNAs and less than 2 nM of the composition is capable of specifically silencing expression of a target gene by at least 65 percent in transfected COS cells.”

Title: RNA-Mediated Interference to Control Disease in Terrestrial and Aquaculture Animals
Number: 20080194504
Filed: Feb. 4, 2005 PCT Filed: Feb. 4, 2005
Lead Inventor: David Kyle, Advanced Bionutrition
“The invention is directed to compositions [such as] feeds, feed supplements, and therapeutic products, and methods for inhibiting an animal pathogen using RNA interference technology,” according to the patent application’s abstract.

Title: Compositions and Methods for Inhibiting Viral Replication
Number: 20080194512
Filed: Dec. 19, 2007
Lead Inventor: Matthias John, Alnylam Europe (Alnylam Pharmaceuticals)
The invention, the patent application’s abstract states, “relates to a double-stranded ribonucleic acid having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3'-untranslated region of a strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the [sense] strand RNA virus, as well as methods for inhibiting viral replication.”

Title: RNAi-Mediated Inhibition of Aquaporin 4 for Treatment of Ocular Neovascularization
Number: 20080194513
Filed: Jan. 28, 2008
Lead Inventor: Rajkumar Patil, Alcon
The patent application, its abstract states, claims “RNA interference … for inhibition of aquaporin 4 to treat conditions associated with neovascularization.”

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.